$KURA

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001422143 0001422143 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24,

Kura Oncology (Nasdaq: KURA) said it will present updated long-term follow-up data from its FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve advanced clear cell RCC at KCRS 2026. The company also noted an ongoing Phase 1b randomized trial of darlifarnib plus cabozantinib vs cabozantinib alone and plans a Phase 3 dose selection for 2028.

Leoni Mollie (Chief Medical Officer) sold 84,929 shares of Kura Oncology, Inc. (KURA) at $9.82 ($0.83M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Several analysts updated ratings and price targets for Kura Oncology (NASDAQ: KURA). On June 4, Cantor Fitzgerald reaffirmed an “overweight” rating, while CLSA and Wells Fargo set new $24.00 targets. On May 28, Oppenheimer and Jefferies set $24.00 targets and Citigroup reaffirmed “market outperform.” On April 14, Lake Street Capital initiated “buy” with a $23.00 target.

Kura Oncology (NASDAQ:KURA) said at TD Cowen’s Oncology Innovation Summit it is building momentum for its newly approved AML therapy KOMZIFTI (ziftomenib) in relapsed/refractory NPM1-mutant AML, citing 85 new patient starts and 157 prescriptions in Q1 and $5.8M revenue. Executives also highlighted darlifarnib+adagrasib solid-tumor response data and updated KOMET-007 results ahead of ASCO and EHA.

Fisher Asset Management LLC opened a new position in Kura Oncology, Inc. (NASDAQ:KURA) in Q4, buying 471,993 shares valued at about $4.9 million, according to Holdings Channel. Other funds also increased stakes, including Jacobs Levy, Qube Research, Nan Fung Trinity, UBS Group and Man Group. KURA last reported EPS of -$0.83 on $18.27 million revenue (vs. $25.97 million consensus).

Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have initiated a Phase 2 registrational clinical trial in Japan for ziftomenib, an oral menin inhibitor aimed at treating relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This step is crucial for potential regulatory approval in Japan, following its FDA approval in November 2025 for similar patient populations in the U.S. The trial seeks to confirm the drug's efficacy and safety, addressing a significant unmet medical need for AML patients.

This article announces an ARS SEC filing by Kura Oncology, Inc. (KURA) on April 10, 2026, at 4:45 PM. The filing has a low impact and neutral sentiment. The article also provides a brief overview of KURA's stock data, rankings, and recent news and SEC filings.

As U.S. stock futures trade higher, investors are focusing on several companies ahead of Wednesday's market open. Delta Air Lines, RPM International, and Constellation Brands are set to release earnings, while Kura Sushi USA reported a narrower loss and Levi Strauss & Co. exceeded expectations and raised its full-year guidance. These companies are poised to be key movers in Wednesday's trading session.

Kura Oncology (KURA) is expected to report a significant year-over-year decline in earnings and lower revenues for Q4 2025. The company is projected to post a quarterly loss of $0.72 per share, with revenues around $29.81 million. The Zacks Earnings ESP indicates a potential negative surprise, making it difficult to predict an earnings beat.